Innovating neurorehabilitation strategies may work to enhance recoveries in acute therapies. Great read! https://t.co/8EO9cFVF8r #medicaltechnology#therapies#medtech
I'm rarely at loss for words, but all I can say is "thank you" to @matthewherper and team for this truly beautiful video and article "A Biotech Executive Faces End-Stage Cancer As A Patient" via @forbes https://t.co/AMP58mBq4D #HPV#cancer#awalkwithpurpose and thx @bradloncar
Dr. Hegde @genentech: Patient selection is going to get more and more complex. It’s hard enough with doublet combinations – what will happen when we have 3 or 4 drug combinations? #SITC2017#Workshop
Dr. Swanton: A serious problem is facing the IO community: Median OS improvements have been modest and are not matched by reduction therapeutic costs. #SITC2017